Agenus Inc. (NASDAQ:AGEN) Shares Sold by Oracle Investment Management Inc.

Oracle Investment Management Inc. cut its stake in shares of Agenus Inc. (NASDAQ:AGEN) by 98.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,500 shares of the biotechnology company’s stock after selling 1,049,463 shares during the period. Agenus makes up 0.3% of Oracle Investment Management Inc.’s holdings, making the stock its 16th biggest holding. Oracle Investment Management Inc. owned approximately 0.08% of Agenus worth $293,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. BNP Paribas Financial Markets grew its position in Agenus by 81.3% in the 1st quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 84,477 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after purchasing an additional 4,134,232 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Agenus by 1,959.9% in the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock valued at $439,000 after purchasing an additional 720,629 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Agenus by 52.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock worth $208,000 after buying an additional 123,058 shares during the period. Finally, Federated Hermes Inc. acquired a new stake in Agenus during the 2nd quarter worth approximately $1,921,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Stock Performance

AGEN opened at $5.30 on Tuesday. Agenus Inc. has a one year low of $4.41 and a one year high of $24.20. The company has a market cap of $111.29 million, a P/E ratio of -0.41 and a beta of 1.36. The business’s 50-day simple moving average is $6.09 and its 200-day simple moving average is $10.20.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) EPS for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The business had revenue of $23.51 million for the quarter, compared to the consensus estimate of $64.73 million. During the same quarter in the prior year, the company earned ($4.00) EPS. As a group, analysts predict that Agenus Inc. will post -10.87 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on AGEN shares. Robert W. Baird downgraded shares of Agenus from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $35.00 to $8.00 in a research note on Friday, July 19th. B. Riley lowered their target price on Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. Baird R W lowered Agenus from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. William Blair downgraded Agenus from an “outperform” rating to a “market perform” rating in a research report on Thursday, July 18th. Finally, StockNews.com cut shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Agenus currently has a consensus rating of “Hold” and a consensus target price of $10.50.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.